Protocol Ledger

NCT07410117 · Phase III · RECRUITING

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Interventional Phase III clinical trial protocol NCT07410117 sponsored by Regeneron Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-09 Enrollment: 1,120 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07410117
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,120 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07410117
Protocol FieldVerified Registry Value
NCT IdentifierNCT07410117
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,120 participants (ESTIMATED)
Registered Start Date2026-03-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07410117
Hospital Research SiteLocationSite Profile
Beth Israel Deaconess Medical CenterBoston, MAOpen Hospital Dossier ->
Memorial Sloan Kettering Cancer CenterNew York, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI